Program for Thursday, May 19th: Talk View

PROGRAM FOR THURSDAY, MAY 19TH: TALK VIEW

Days:

previous day

next day

all days

View: with abstracts session overview

8:30

9:00

9:30

10:00

10:30

11:00

11:30

12:00

12:30

13:00

13:30

14:00

14:30

15:00

15:30

16:00

16:30

17:00

17:30

18:00

18:30

19:00

19:30

20:00

20:30

21:00

21:30

22:00

22:30

23:00

23:30

08:30-10:00

Innovative strategies for kidney bioengineering

Ton Rabelink

08:30-10:00

Engineering cells (and organs) to evade immune detection

Rainer Blasczyk

08:30-10:00

HLA-specific CAR Tregs in organ transplantation - from bench tot bedside

Megan Levings

08:30-10:00 Plenary session: Tolerance Through Gene Therapy (Screened)

10:00-10:30 Poster Viewing

10:30-12:00

Solid phase assays to determine HLA antibodies: pros and cons

Stefan Schaub

10:30-12:00

Utility of the virtual crossmatch in kidney transplantation

David Turner

10:30-12:00

Modes of identifying acceptable vs non-acceptable mismatches in kidney transplantation

Nils Lachmann

10:30-12:00

Mucosal tolerance

Janneke Samson

10:30-12:00

Tolerance in kidney transplantation

Raphael Duivenvoorden

10:30-12:00

Tolerance in stem cell transplantation

Femke van Wijke

10:30-12:00

High throughput sequencing monitoring of the T-cell receptor (TCR) repertoire after allogeneic hematopoietic stem cell transplantation, a six years follow-up: main influence of Cytomegalovirus in shaping the repertoire’s diversity and

Buhler et.al

10:30-12:00

Stem cell donation probability by age, gender, CMV status and HLA genotype frequency

J. Sauter, D. Schefzyk, J.A. Hofmann, J. Pruschke, T. Mengling, A.H. Schmidt

10:30-12:00

CD147 expression and polymorphism as markers of cytomegalovirus infection in acute myeloid leukaemia patients following allogeneic stem cell

Łacina et.al

10:30-12:00

Matching beyond the HLA name: a new classification of HLA-allele mismatches based on peptide binding

K. Osoegawa, K. Cunanan, S. Spellman, A. Bertaina, M.A. Fernández-Viña

10:30-12:00

A core group of structurally similar HLA-DPB1 alleles drives permissiveness after hematopoietic cell

Arrieta-Bolaños et.al

10:30-12:00

CD4- and CD8-T cell receptor repertoires reconstitution after hematopoietic stem cell

Calderin Sollet et.al

10:30-12:00

Donor rs2204985 AA Genotype Associates with Worse Outcome after 9/10 HLA-matched Unrelated HSCT

Tsamadou et.al

10:30-12:00

Permissiveness of HLA mismatch depends much on haplotype phase location of the mismatch

Nowak et.al

10:30-12:00

The peptide editor HLA-DM modulates tumor associated antigen presentation by HLA-DP in the monocytic leukemia cell line

P. Crivello, T. Bracht, S. Layer, J. Peters, B. Sitek, K. Fleischhauer

10:30-12:00

Comparative analysis of human and chimpanzee full-length genomic Mhc class I A sequences revealed unreported signatures of evolutionary

Corrine Heijmans, Ronald E. Bontrop, Alicia Sanchez-Mazas, Natasja G. de Groot

10:30-12:00

Discovery of a MICA gene duplication with strong linkage to HLA-B*27:02

Klussmeier, Massalski, Schefzyk, Schäfer, Sauter, Schmidt, Lange

10:30-12:00

HLA global map: analysis of frequency variation in >200 populations reveals different patterns for class I and class

Esteban Arrieta-Bolaños, Diana Iraíz Hernández-Zaragoza, Rodrigo Barquera

10:30-12:00

Human herpesvirus diversity is altered in HLA class I binding peptides

William Palmer, Marco Telford, Arcadi Navarro, Gabriel Santpere, Paul Norman

10:30-12:00

Completing and Expanding the Human Genome Reference of the MHC

Houwaart et.al

10:30-12:00

A refined topography of the HLA molecular landscape across populations

Nunes et.al

10:30-12:00

Human and cynomolgus macaque Mhc-DQB transcripts may share alternative splice event skipping exon 4 encoding the transmembrane

N.G. de Groot, N. de Groot, A.J. de Vos-Rouweler, J. Bruijnesteijn, R.E. Bontrop

12:00-13:00 Poster Viewing

13:00-13:45 Industry Sponsored Symposium: Oxford Nanopore Technologies

13:00-13:45 Industry Sponsored Symposium: One Lambda, Inc. A Thermo Fisher Scientific Brand

13:00-13:45 Industry Sponsored Symposium: Omixon

13:00-13:45 Industry Sponsored Symposium: Immucor

14:00-15:30

Developing bio informatics tools in NGS

Gerhard Schöfl

14:00-15:30

NGS-based HLA typing in practice

Neema Mayor

14:00-15:30

TCR sequencing with NGS

Peter de Greef

14:00-15:30

Combined kidney and hematopoietic cell transplantation for tolerance induction between HLA matched sibling donor-recipient

Israeli, Nesher, Rahamimov, Shargian, Pasvolsky, Fenig, Mor, Yeshurun

14:00-15:30

Single-cell sequence analyses of circulating T follicular helper cells during antibody-mediated

Emma Peereboom, Kirsten Geneugelijk, Karin Boer, Carla Baan, Eric Spierings

14:00-15:30

Endothelial permeability to anti-HLA antibodies: towards new targets to prevent transplant

Ferrary, Swiader, Smirnova, Laffargue, Negre-Salvayre, Congy-Jolivet

14:00-15:30

Site-directed mutagenesis of HLA molecules reveals the amino acids crucial for monoclonal antibody

Meng et.al

14:00-15:30

Tacrolimus withdrawal after mesenchymal stromal cell therapy is associated with donor-specific antibody formation in kidney transplant

S. Bezstarosti, M.E.J. Reinders, J.W. de Fijter, S. Heidt

14:00-15:30

The IgG panel from peripheral CD38+/138+ B cells represents a resilient surrogate marker for safe donor/recipient

Bade-Doeding, Schleumann, Collmann, Hiemisch, Placzko, Blasczyk

14:00-15:30

Genome-wide mismatch and deletion analysis in kidney transplantation

Markkinen, Helanterä, Lauronen, Lempinen, Partanen, Hyvärinen

14:00-15:30

Association of SARS-CoV-2 vaccination with the development of anti-HLA antibodies in kidney transplant

Fylaktou et.al

14:00-15:30

HLA-ASSOCIATION STUDY WITH MORE THAN 16,000 PARTICIPANTS SHOWS NO HETEROZYGOTE ADVANTAGE FOR COVID-19 AND NO PROTECTIVE

Schetelig et.al

14:00-15:30

MHC Haplotyping of SARS-CoV-2 Patients: HLA Subtypes Are Not Associated with the Presence and Severity of COVID-19 in the Israeli

Shay Ben Shachar, Noam Barda, Sapir Israeli, Sigal Manor, Yoram Louzoun

14:00-15:30

Results from the HLACOVID-ITALIA study: an unexpected correlation between HLA-DP antigen load and COVID-19

Rovatti et.al

14:00-15:30

Polymorphism of the HLA system and weak antibody response to BNT162b2 mRNA vaccine

Crocchiolo et.al

14:00-15:30

Loss of tumor HLA class I and PD-L1 expression in bladder cancer is associated with higher tumor grade and poor survival

Gil-Julio, Perea, Torres, Cozar, Garrido, Aptsiauri, Ruiz-Cabello

14:00-15:30

HLA class II immune editing in JAK2V617 and CALR mutation driven oncogenesis

M. Ivanova, G. Tsvetkova, L. Tsvetelin, I. Micheva, E. Hadjiev, V. Shivarov

14:00-15:30

HLA-disease association and pleiotropy landscape in over 235 000 Finns

Jukka Partanen, Kati Hyvärinen, Satu Koskela, Jarmo Ritari

14:00-15:30

Functional impact of coding risk variant RUNX3 on brain-homing CD8+ T cells in multiple sclerosis

Koetzier et.al

14:00-15:30

Case studies on DSA

Christine Voorter

14:00-15:30

Case studies on DSA

Laura Bungener

14:00-15:30

Case studies on DSA

Michael Eikmans

14:00-15:30

Case studies on DSA

Arnold van der Meer

15:30-16:00 Poster Viewing

16:00-17:30

Cell- and tissue-specific cellular and molecular mechanisms that influence tolerance vs anti-tumor immunity upon

Ronjon Chakraverty

16:00-17:30

HLA-DQA/DQB permissiveness in stem cell transplantation

Effie Petersdorf

16:00-17:30

gd-T cells and future perspectives of stem cell transplantation

Jurgen Kuball

16:00-17:30 Plenary session: Future Perspectives in Stem Cell Transplantation (Screening)

17:30-19:00 General Assembly

19:30-23:59 Networking Event

10:00-10:30 Coffee Break

12:00-13:00 Lunch Break

15:30-16:00 Coffee Break